Resolve Therapeutics announced that the company raised enough funds to allow them to test their anti-interferon therapy for lupus in 2013. One of the company's founders, Keith Elkon, MD, is a member of the Lupus Research Institute's Scientific Advisory Board. He is the Mannik-Henderson Professor of Medicine and Adjunct Professor of Immunology and Head, Division of Rheumatology at University of Washington.
“These funds give Resolve the necessary resources to advance our investigational lupus compound RSLV-132 into clinical trials, which we expect to start in mid-2013,” said James Posada, Ph.D., Chief Executive Officer of Resolve. “We are excited about this novel new approach to treating lupus, which eliminates the immune complexes that represent one of the central causes of the disease.”
“Resolve has made significant progress in the development of RSLV-132, from the company’s formation around an academic concept developed at the University of Washington in early 2010 to the creation of a clinical candidate currently completing IND-enabling studies,” said Somu Subramaniam, Founder and Managing Partner of New Science Ventures. “To have achieved this accomplishment on total funding of less than $3 million to date is strong validation of Resolve’s business model for capital-efficient drug development.”